Carlos Kamiya-Matsuoka1, David Cachia1, Adriana Olar1, Terri S Armstrong1, Mark R Gilbert1. 1. Department of Neuro-Oncology , The University of Texas MD Anderson Cancer Center , Houston, Texas (C.K.-M., D.C., T.S.A., M.R.G.); Department of Family Health , The University of Texas Health Science Center School of Nursing , Houston, Texas (T.S.A.); Department of Pathology , The University of Texas MD Anderson Cancer Center , Houston, Texas (A.O.).
Abstract
BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic encephalopathic state associated with reversible cerebral vasogenic edema. It is an increasingly recognized occurrence in the oncology population. However, it is very uncommon in patients with primary brain tumors (PBTs). The aim of this study was to analyze the clinicoradiological features and report the clinical outcomes of PRES in PBT patients. METHODS: We identified 4 cases with PBT who developed PRES at MD Anderson Cancer Center (MDACC) between 2012 and 2014. Clinical and radiological data were abstracted from their records. In addition, we also solicited 8 cases from the literature. RESULTS: The median age at PRES onset was 19 years, male-to-female ratio was 1:1, and the syndrome occurred in patients with ependymoma (n = 4), glioblastoma (n = 3), diffuse intrinsic pontine glioma (DIPG; n = 3), juvenile pilocytic astrocytoma (n = 1), and atypical meningioma (n = 1). Two glioblastomas and 2 DIPG cases received bevacizumab and vandetanib before the onset of symptoms, respectively. The most common clinical presentation was seizures (n = 7). Three MDACC patients recovered completely in 3-4 weeks after the onset of symptoms. One patient died due to active cancer and several comorbidities including PRES. CONCLUSIONS: Hypertension seems to be the most important coexisting risk factor for development of PRES; however, the potential effects of chemotherapeutic agents in the pathogenesis of PRES should also be examined. The clinicoradiological course of PRES in PBT patients did not vary from the classical descriptions of PRES found in other causes. PRES must be considered as part of the differential diagnosis in patients with PBTs presenting with seizures or acute encephalopathy.
BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic encephalopathic state associated with reversible cerebral vasogenic edema. It is an increasingly recognized occurrence in the oncology population. However, it is very uncommon in patients with primary brain tumors (PBTs). The aim of this study was to analyze the clinicoradiological features and report the clinical outcomes of PRES in PBTpatients. METHODS: We identified 4 cases with PBT who developed PRES at MD Anderson Cancer Center (MDACC) between 2012 and 2014. Clinical and radiological data were abstracted from their records. In addition, we also solicited 8 cases from the literature. RESULTS: The median age at PRES onset was 19 years, male-to-female ratio was 1:1, and the syndrome occurred in patients with ependymoma (n = 4), glioblastoma (n = 3), diffuse intrinsic pontine glioma (DIPG; n = 3), juvenile pilocytic astrocytoma (n = 1), and atypical meningioma (n = 1). Two glioblastomas and 2 DIPG cases received bevacizumab and vandetanib before the onset of symptoms, respectively. The most common clinical presentation was seizures (n = 7). Three MDACC patients recovered completely in 3-4 weeks after the onset of symptoms. One patient died due to active cancer and several comorbidities including PRES. CONCLUSIONS:Hypertension seems to be the most important coexisting risk factor for development of PRES; however, the potential effects of chemotherapeutic agents in the pathogenesis of PRES should also be examined. The clinicoradiological course of PRES in PBTpatients did not vary from the classical descriptions of PRES found in other causes. PRES must be considered as part of the differential diagnosis in patients with PBTs presenting with seizures or acute encephalopathy.
Authors: Akash J Patel; Benjamin D Fox; Daniel H Fulkerson; Sasidhar Yallampalli; Anna Illner; William E Whitehead; Daniel J Curry; Thomas G Luerssen; Andrew Jea Journal: J Neurosurg Pediatr Date: 2010-10 Impact factor: 2.375
Authors: Alberto Broniscer; Justin N Baker; Michael Tagen; Arzu Onar-Thomas; Richard J Gilbertson; Andrew M Davidoff; Atmaram S Pai Panandiker; Atmaram Pai Panandiker; Wing Leung; Thomas K Chin; Clinton F Stewart; Mehmet Kocak; Christopher Rowland; Thomas E Merchant; Sue C Kaste; Amar Gajjar Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Lain Hermes González Quarante; José Hinojosa Mena-Bernal; Beatriz Pascual Martín; Marta Ramírez Carrasco; María Jesús Muñoz Casado; Ana Martínez de Aragón; Rogelio Simón de las Heras Journal: Childs Nerv Syst Date: 2015-11-19 Impact factor: 1.475
Authors: Miguel Marigil; Naiara Martinez-Velez; Pablo D Domínguez; Miguel Angel Idoate; Enric Xipell; Ana Patiño-García; Marisol Gonzalez-Huarriz; Marc García-Moure; Marie-Pierre Junier; Hervé Chneiweiss; Elías El-Habr; Ricardo Diez-Valle; Sonia Tejada-Solís; Marta M Alonso Journal: PLoS One Date: 2017-01-20 Impact factor: 3.240